McKesson, Oracle fight for Veradigm

McKesson and Oracle are among the final bidders vying to acquire EMR data company Veradigm (OTC: MDRX), sources tell Axios. Why it matters: Veradigm, née Allscripts, is likely to command a valuation above its $1 billion market cap, they say, citing lower risk of antitrust scrutiny in the incoming administration. Between the lines: McKesson (NYSE: MCK), Oracle (NYSE: ORCL) and private equity bidder Thoma Bravo — all of whom have rich medical data machines already — could have feasibly asked for a slight discount on valuation given heightened antitrust oversight,...